In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for purifying bacteriophage. Provided herein is are practicable methods, or protocols, that are “Good Laboratory Manufacturing Practice” (GLMP), for phage isolation, selection, liter-scaled cultivation, and purification. In alternative embodiments, GLMP protocols as provided herein employ membrane filtration processes to yield at least about 300 treatment doses at about 10.sup.9 plaque-forming units with endotoxin levels within human therapeutic regulatory limits. In alternative embodiments, provided are formulations or pharmaceutical preparations of bacteriophage comprising 10.sup.9 PFU, 10.sup.10 PFU, 10.sup.11 PFU, or 10.sup.12 PFU or more per unit dose and endotoxin levels below about 5.5 EU.Math.mL.sup.−1, or below about 5.0 EU.Math.mL.sup.−1.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for purifying bacteriophage. Provided herein is are practicable methods, or protocols, that are “Good Laboratory Manufacturing Practice” (GLMP), for phage isolation, selection, liter-scaled cultivation, and purification. In alternative embodiments, GLMP protocols as provided herein employ membrane filtration processes to yield at least about 300 treatment doses at about 10.sup.9 plaque-forming units with endotoxin levels within human therapeutic regulatory limits. In alternative embodiments, provided are formulations or pharmaceutical preparations of bacteriophage comprising 10.sup.9 PFU, 10.sup.10 PFU, 10.sup.11 PFU, or 10.sup.12 PFU or more per unit dose and endotoxin levels below about 5.5 EU.Math.mL.sup.−1, or below about 5.0 EU.Math.mL.sup.−1.

A method of purifying a composition comprising a group B adenovirus, for example comprising a purification step of: subjecting a composition comprising said group B adenovirus to diafiltration employing a diafiltration-buffer with a conductivity of at least 180 mScm.sup.−1, for example a conductivity of 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 290 mScm.sup.−1. Also provided is a composition obtained using the purification method disclosed herein.

A method of purifying a composition comprising a group B adenovirus, for example comprising a purification step of: subjecting a composition comprising said group B adenovirus to diafiltration employing a diafiltration-buffer with a conductivity of at least 180 mScm.sup.−1, for example a conductivity of 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, or 290 mScm.sup.−1. Also provided is a composition obtained using the purification method disclosed herein.

One aspect of the invention provides a method of generating bacteriophages adapted to infect a target bacterial strain. The method comprises: providing host bacteria that are susceptible to phage as input to a host chemostat containing phage; providing target bacteria that are related to the host bacteria, but not susceptible to phage as input to a target chemostat containing phage; filtering outflows from the host chemostat and the target chemostat to isolate phage from the populations of the host bacteria, the target bacteria, and macromolecules; combining the outflows; and introducing the combined outflow into each of the host chemostat and the target chemostat.

A method of detecting a species, strain or type of bacteria includes mixing a labeled bacteriophage including a label that is detectible via a detection system with a bacterial culture including the species, strain or type of bacteria to which the labeled bacteriophage selectively binds and using the detection system to detect the labeled bacteriophage bound to the species, strain or type of bacteria.

A method of detecting a species, strain or type of bacteria includes mixing a labeled bacteriophage including a label that is detectible via a detection system with a bacterial culture including the species, strain or type of bacteria to which the labeled bacteriophage selectively binds and using the detection system to detect the labeled bacteriophage bound to the species, strain or type of bacteria.

Methods of producing and purifying viruses using density gradient ultracentrifugation. The methods are suitable for large scale production, and for viruses produced in eggs or in cell culture.

Methods of producing and purifying viruses using density gradient ultracentrifugation. The methods are suitable for large scale production, and for viruses produced in eggs or in cell culture.

The present invention is directed to viral vectors and methods of their production and use.